|
1
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Winchester DA, Till C, Goodman PJ, Tangen
CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL,
Thompson IM, et al: Variation in genes involved in the immune
response and prostate cancer risk in the placebo arm of the
Prostate Cancer Prevention Trial. Prostate. 75:1403–1418. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sfanos KS, Isaacs WB and De Marzo AM:
Infections and inflammation in prostate cancer. Am J Clin Exp Urol.
1:3–11. 2013.PubMed/NCBI
|
|
4
|
Haverkamp J, Charbonneau B and Ratliff TL:
Prostate inflammation and its potential impact on prostate cancer:
A current review. J Cell Biochem. 103:1344–1353. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanda Y, Osaki M and Okada F:
Chemopreventive strategies for inflammation-related carcinogenesis:
Current status and future direction. Int J Mol Sci. 18:E8672017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McKown RL, Orle KA, Chen T and Craig NL:
Sequence requirements of Escherichia coli attTn7, a specific site
of transposon Tn7 insertion. J Bacteriol. 170:352–358. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun B and Karin M: The therapeutic value
of targeting inflammation in gastrointestinal cancers. Trends
Pharmacol Sci. 35:349–357. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nguyen DP, Li J, Yadav SS and Tewari AK:
Recent insights into NF-κB signalling pathways and the link between
inflammation and prostate cancer. BJU Int. 114:168–176. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang JJ, Chu HX, Jiang ZY, Zhang XJ, Sun
HP and You QD: Recent advances in the structure-based and
ligand-based design of IKKβ inhibitors as anti-inflammation and
anti-cancer agents. Curr Med Chem. 21:3893–3917. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gasparian AV, Yao YJ, Kowalczyk D, Lyakh
LA, Karseladze A, Slaga TJ and Budunova IV: The role of IKK in
constitutive activation of NF-kappaB transcription factor in
prostate carcinoma cells. J Cell Sci. 115:141–151. 2002.PubMed/NCBI
|
|
11
|
Verzella D, Fischietti M, Capece D,
Vecchiotti D, Del Vecchio F, Cicciarelli G, Mastroiaco V, Tessitore
A, Alesse E and Zazzeroni F: Targeting the NF-κB pathway in
prostate cancer: A promising therapeutic approach? Curr Drug
Targets. 17:311–320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakamura Y, Felizola SJ, Kurotaki Y,
Fujishima F, McNamara KM, Suzuki T, Arai Y and Sasano H: Cyclin D1
(CCND1) expression is involved in estrogen receptor beta (ERβ) in
human prostate cancer. Prostate. 73:590–595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu WF, Tan XJ, Dai YB, Krishnan V, Warner
M and Gustafsson JA: Targeting estrogen receptor β in microglia and
T cells to treat experimental autoimmune encephalomyelitis. Proc
Natl Acad Sci USA. 110:3543–3548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mak P, Li J, Samanta S and Mercurio AM:
ERβ regulation of NF-κB activation in prostate cancer is mediated
by HIF-1. Oncotarget. 6:40247–40254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soshilov A and Denison MS: Role of the
Per/Arnt/Sim domains in ligand-dependent transformation of the aryl
hydrocarbon receptor. J Biol Chem. 283:32995–33005. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao H, Lo YH, Ma L, Waltz SE, Gray JK,
Hung MC and Wang SC: Targeting tyrosine phosphorylation of PCNA
inhibits prostate cancer growth. Mol Cancer Ther. 10:29–36. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen H, Zeng G, Sun B, Cai X, Bi L, Tang G
and Yang Y: A polysaccharide from Glycyrrhiza inflata Licorice
inhibits proliferation of human oral cancer cells by inducing
apoptosis via mitochondrial pathway. Tumour Biol. 36:4825–4831.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang S, Qiu M, Xia W, Xu Y, Mao Q, Wang J,
Dong G, Xu L, Yang X and Yin R: Glypican-5 suppresses
epithelial-mesenchymal transition of the lung adenocarcinoma by
competitively binding to Wnt3a. Oncotarget. 7:79736–79746.
2016.PubMed/NCBI
|
|
20
|
Schetter AJ, Heegaard NH and Harris CC:
Inflammation and cancer: Interweaving microRNA, free radical,
cytokine and p53 pathways. Carcinogenesis. 31:37–49. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu P, Cai F, Liu X and Guo L: Sesamin
inhibits lipopolysaccharide-induced proliferation and invasion
through the p38-MAPK and NF-κB signaling pathways in prostate
cancer cells. Oncol Rep. 33:3117–3123. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mantovani A: Cancer: Inflammation by
remote control. Nature. 435:752–753. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsu RY, Chan CH, Spicer JD, Rousseau MC,
Giannias B, Rousseau S and Ferri LE: LPS-induced TLR4 signaling in
human colorectal cancer cells increases beta1 integrin-mediated
cell adhesion and liver metastasis. Cancer Res. 71:1989–1998. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li J, Chong T, Wang Z, Chen H and Li H,
Cao J, Zhang P and Li H: A novel anticancer effect of resveratrol:
Reversal of epithelialmesenchymal transition in prostate cancer
cells. Mol Med Rep. 10:1717–1724. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Im HJ, Park NH, Kwon YJ, Shin S, Kim D and
Chun YJ: Bacterial lipopolysaccharides induce steroid sulfatase
expression and cell migration through IL-6 pathway in human
prostate cancer cells. Biomol Ther (Seoul). 20:556–561. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Michalaki V, Syrigos K, Charles P and
Waxman J: Serum levels of IL-6 and TNF-alpha correlate with
clinicopathological features and patient survival in patients with
prostate cancer. Br J Cancer. 90:2312–2316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shaddox LM, Gonçalves PF, Vovk A, Allin N,
Huang H, Hou W, Aukhil I and Wallet SM: LPS-induced inflammatory
response after therapy of aggressive periodontitis. J Dent Res.
92:702–708. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Christoforou P, Christopoulos PF and
Koutsilieris M: The role of estrogen receptor beta in prostate
cancer. Mol Med. 20:427–434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lombardi AP, Pisolato R, Vicente CM,
Lazari MF, Lucas TF and Porto CS: Estrogen receptor beta (ERβ)
mediates expression of β-catenin and proliferation in prostate
cancer cell line PC-3. Mol Cell Endocrinol. 430:12–24. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu WF, Maneix L, Insunza J, Nalvarte I,
Antonson P, Kere J, Yu NY, Tohonen V, Katayama S, Einarsdottir E,
et al: Estrogen receptor β, a regulator of androgen receptor
signaling in the mouse ventral prostate. Proc Natl Acad Sci USA.
114:E3816–e3822. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Elo T, Yu L, Valve E, Mäkelä S and
Härkönen P: Deficiency of ERβ and prostate tumorigenesis in FGF8b
transgenic mice. Endocr Relat Cancer. 21:677–690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Weihua Z, Lathe R, Warner M and Gustafsson
JA: An endocrine pathway in the prostate, ERbeta, AR,
5alpha-androstane-3beta, 17beta-diol, and CYP7B1, regulates
prostate growth. Proc Natl Acad Sci USA. 99:13589–13594. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Prins GS and Korach KS: The role of
estrogens and estrogen receptors in normal prostate growth and
disease. Steroids. 73:233–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dondi D, Piccolella M, Biserni A, Della
Torre S, Ramachandran B, Locatelli A, Rusmini P, Sau D, Caruso D,
Maggi A, et al: Estrogen receptor beta and the progression of
prostate cancer: Role of 5alpha-androstane-3beta, 17beta-diol.
Endocr Relat Cancer. 17:731–742. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guerini V, Sau D, Scaccianoce E, Rusmini
P, Ciana P, Maggi A, Martini PG, Katzenellenbogen BS, Martini L,
Motta M and Poletti A: The androgen derivative
5alpha-androstane-3beta, 17beta-diol inhibits prostate cancer cell
migration through activation of the estrogen receptor beta subtype.
Cancer Res. 65:5445–5453. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Piccolella M, Crippa V, Messi E, Tetel MJ
and Poletti A: Modulators of estrogen receptor inhibit
proliferation and migration of prostate cancer cells. Pharmacol
Res. 79:13–20. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huong PT, Moon DO, Kim SO, Kim KE, Jeong
SJ, Lee KW, Lee KS, Jang JH, Erikson RL, Ahn JS and Kim BY:
Proteasome inhibitor-I enhances tunicamycin-induced
chemosensitization of prostate cancer cells through regulation of
NF-κB and CHOP expression. Cell Signal. 23:857–865. 2011.
View Article : Google Scholar : PubMed/NCBI
|
